Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer

Science Translational Medicine

Volumn 5, Issue 216, 2013, Pages

  Yasuda, Hiroyuki ^a,b   Park, Eunyoung ^a   Yun, Cai Hong ^c   Sng, Natasha J ^a   Lucena Araujo, Antonio R ^a   Yeo, Wee Lee ^a   Huberman, Mark S ^a   Cohen, David W ^a,i   Nakayama, Sohei ^a   Ishioka, Kota ^b   Yamaguchi, Norihiro ^a   Hanna, Megan ^a,d   Oxnard, Geoffrey R ^a,e   Lathan, Christopher S ^a,e   Moran, Teresa ^f   Sequist, Lecia V ^f   Chaft, Jamie E ^g   Riely, Gregory J ^g   Arcila, Maria E ^g   Soo, Ross A ^h   Meyerson, Matthew ^a,d,e   Eck, Michael J ^a   Kobayashi, Susumu S ^a   Costa, Daniel B ^a   more..

^a HARVARD MEDICAL SCHOOL   (United States)

^b KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^d MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

^g MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^h NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

ⁱ THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; PROTEIN KINASE B; PROTEIN TYROSINE KINASE INHIBITOR;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER RESISTANCE; CANCER SURVIVAL; CELL KILLING; CONCENTRATION RESPONSE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG EFFICACY; DRUG RESPONSE; EGFR GENE; ENZYME KINETICS; EXON; GENE MUTATION; HUMAN; HUMAN CELL; LUNG CANCER; LUNG NON SMALL CELL CANCER; ONCOGENE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN PHOSPHORYLATION; STRUCTURE ANALYSIS; UPREGULATION;

AMINO ACID SEQUENCE; ANTINEOPLASTIC AGENTS; BASE SEQUENCE; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CRYSTALLOGRAPHY, X-RAY; DNA, NEOPLASM; DRUG RESISTANCE, NEOPLASM; EXONS; GENES, ERBB-1; HUMANS; LUNG NEOPLASMS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTAGENESIS, INSERTIONAL; MUTATION; PROTEIN CONFORMATION; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; STRUCTURAL HOMOLOGY, PROTEIN; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84892631191     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3007205     Document Type: Article

References (70)

1. R. Siegel, D. Naishadham, A. Jemal, Cancer statistics, 2013. CA Cancer J. Clin. 63, 11-30 (2013).
2. T. J. Lynch, D. W. Bell, R. Sordella, S. Gurubhagavatula, R. A. Okimoto, B. W. Brannigan, P. L. Harris, S. M. Haserlat, J. G. Supko, F. G. Haluska, D. N. Louis, D. C. Christiani, J. Settleman, D. A. Haber, Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350, 2129-2139 (2004).
3. J. G. Paez, P. A. Jänne, J. C. Lee, S. Tracy, H. Greulich, S. Gabriel, P. Herman, F. J. Kaye, N. Lindeman, T. J. Boggon, K. Naoki, H. Sasaki, Y. Fujii, M. J. Eck, W. R. Sellers, B. E. Johnson, M. Meyerson, EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304, 1497-1500 (2004).
4. W. Pao, V. Miller, M. Zakowski, J. Doherty, K. Politi, I. Sarkaria, B. Singh, R. Heelan, V. Rusch, L. Fulton, E. Mardis, D. Kupfer, R. Wilson, M. Kris, H. Varmus, EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl. Acad. Sci. U.S.A. 101, 13306-13311 (2004).
5. H. Shigematsu, L. Lin, T. Takahashi, M. Nomura, M. Suzuki, I. I. Wistuba, K. M. Fong, H. Lee, S. Toyooka, N. Shimizu, T. Fujisawa, Z. Feng, J. A. Roth, J. Herz, J. D. Minna, A. F. Gazdar, Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J. Natl. Cancer Inst. 97, 339-346 (2005).
6. L. V. Sequist, D. W. Bell, T. J. Lynch, D. A. Haber, Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J. Clin. Oncol. 25, 587-595 (2007).
7. G. J. Riely, K. A. Politi, V. A. Miller, W. Pao, Update on epidermal growth factor receptor mutations in non-small cell lung cancer. Clin. Cancer Res. 12, 7232-7241 (2006).
8. M. Tokumo, S. Toyooka, K. Kiura, H. Shigematsu, K. Tomii, M. Aoe, K. Ichimura, T. Tsuda, M. Yano, K. Tsukuda, M. Tabata, H. Ueoka, M. Tanimoto, H. Date, A. F. Gazdar, N. Shimizu, The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. Clin. Cancer Res. 11, 1167-1173 (2005).
9. K. Politi, M. F. Zakowski, P. D. Fan, E. A. Schonfeld, W. Pao, H. E. Varmus, Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. Genes Dev. 20, 1496-1510 (2006).
10. H. Ji, D. Li, L. Chen, T. Shimamura, S. Kobayashi, K. McNamara, U. Mahmood, A. Mitchell, Y. Sun, R. Al-Hashem, L. R. Chirieac, R. Padera, R. T. Bronson, W. Kim, P. A. Jänne, G. I. Shapiro, D. Tenen, B. E. Johnson, R. Weissleder, N. E. Sharpless, K. K. Wong, The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. Cancer Cell 9, 485-495 (2006).
11. S. V. Sharma, D. W. Bell, J. Settleman, D. A. Haber, Epidermal growth factor receptor mutations in lung cancer. Nat. Rev. Cancer 7, 169-181 (2007).
12. K. S. Nguyen, S. Kobayashi, D. B. Costa, Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. Clin. Lung Cancer 10, 281-289 (2009).
13. D. B. Costa, B. Halmos, A. Kumar, S. T. Schumer, M. S. Huberman, T. J. Boggon, D. G. Tenen, S. Kobayashi, BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations. PLOS Med. 4, 1669-1679 (2007).
14. M. S. Cragg, J. Kuroda, H. Puthalakath, D. C. Huang, A. Strasser, Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics. PLOS Med. 4, 1681-1689 (2007).
15. Y. Gong, R. Somwar, K. Politi, M. Balak, J. Chmielecki, X. Jiang, W. Pao, Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas. PLOS Med. 4, e294 (2007).
16. J. Deng, T. Shimamura, S. Perera, N. E. Carlson, D. Cai, G. I. Shapiro, K. K. Wong, A. Letai, Proapoptotic BH3-only BCL-2 family protein BIM connects death signaling from epidermal growth factor receptor inhibition to the mitochondrion. Cancer Res. 67, 11867-11875 (2007).
17. L. V. Sequist, R. G. Martins, D. Spigel, S. M. Grunberg, A. Spira, P. A. Jänne, V. A. Joshi, D. McCollum, T. L. Evans, A. Muzikansky, G. L. Kuhlmann, M. Han, J. S. Goldberg, J. Settleman, A. J. Iafrate, J. A. Engelman, D. A. Haber, B. E. Johnson, T. J. Lynch, First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J. Clin. Oncol. 26, 2442-2449 (2008).
18. D. B. Costa, S. Kobayashi, D. G. Tenen, M. S. Huberman, Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers. Lung Cancer 58, 95-103 (2007).
19. R. Rosell, T. Moran, C. Queralt, R. Porta, F. Cardenal, C. Camps, M. Majem, G. Lopez-Vivanco, D. Isla, M. Provencio, A. Insa, B. Massuti, J. L. Gonzalez-Larriba, L. Paz-Ares, I. Bover, R. Garcia-Campelo, M. A. Moreno, S. Catot, C. Rolfo, N. Reguart, R. Palmero, J. M. Sánchez, R. Bastus, C. Mayo, J. Bertran-Alamillo, M. A. Molina, J. J. Sanchez, M. Taron; Spanish Lung Cancer Group, Screening for epidermal growth factor receptor mutations in lung cancer. N. Engl. J. Med. 361, 958-967 (2009).
20. M. Maemondo, A. Inoue, K. Kobayashi, S. Sugawara, S. Oizumi, H. Isobe, A. Gemma, M. Harada, H. Yoshizawa, I. Kinoshita, Y. Fujita, S. Okinaga, H. Hirano, K. Yoshimori, T. Harada, T. Ogura, M. Ando, H. Miyazawa, T. Tanaka, Y. Saijo, K. Hagiwara, S. Morita, T. Nukiwa; North-East Japan Study Group, Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N. Engl. J. Med 362, 2380-2388 (2010).
21. T. Mitsudomi, S. Morita, Y. Yatabe, S. Negoro, I. Okamoto, J. Tsurutani, T. Seto, M. Satouchi, H. Tada, T. Hirashima, K. Asami, N. Katakami, M. Takada, H. Yoshioka, K. Shibata, S. Kudoh, E. Shimizu, H. Saito, S. Toyooka, K. Nakagawa, M. Fukuoka; West Japan Oncology Group, Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial. Lancet Oncol. 11, 121-128 (2010).
22. T. S. Mok, Y. L. Wu, S. Thongprasert, C. H. Yang, D. T. Chu, N. Saijo, P. Sunpaweravong, B. Han, B. Margono, Y. Ichinose, Y. Nishiwaki, Y. Ohe, J. J. Yang, B. Chewaskulyong, H. Jiang, E. L. Duffield, C. L. Watkins, A. A. Armour, M. Fukuoka, Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361, 947-957 (2009).
23. C. Zhou, Y. L. Wu, G. Chen, J. Feng, X. Q. Liu, C. Wang, S. Zhang, J. Wang, S. Zhou, S. Ren, S. Lu, L. Zhang, C. Hu, C. Hu, Y. Luo, L. Chen, M. Ye, J. Huang, X. Zhi, Y. Zhang, Q. Xiu, J. Ma, L. Zhang, C. You, Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): A multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 12, 735-742 (2011).
24. L. V. Sequist, J. C. Yang, N. Yamamoto, K. O'Byrne, V. Hirsh, T. Mok, S. L. Geater, S. Orlov, C. M. Tsai, M. Boyer, W. C. Su, J. Bennouna, T. Kato, V. Gorbunova, K. H. Lee, R. Shah, D. Massey, V. Zazulina, M. Shahidi, M. Schuler, Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J. Clin. Oncol. 31, 3327-3334 (2013).
25. M. He, M. Capelletti, K. Nafa, C. H. Yun, M. E. Arcila, V. A. Miller, M. S. Ginsberg, B. Zhao, M. G. Kris, M. J. Eck, P. A. Jänne, M. Ladanyi, G. R. Oxnard, EGFR exon 19 insertions: A new family of sensitizing EGFR mutations in lung adenocarcinoma. Clin. Cancer Res. 18, 1790-1797 (2012).
26. T. Mitsudomi, Y. Yatabe, Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer. FEBS J. 277, 301-308 (2010).
27. T. Mitsudomi, Y. Yatabe, Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci. 98, 1817-1824 (2007).
28. P. Yeh, H. Chen, J. Andrews, R. Naser, W. Pao, L. Horn, DNA-mutation Inventory to Refine and Enhance Cancer Treatment (DIRECT): A catalog of clinically relevant cancer mutations to enable genome-directed anticancer therapy. Clin. Cancer Res. 19, 1894-1901 (2013).
29. Y. L. Choi, M. Soda, Y. Yamashita, T. Ueno, J. Takashima, T. Nakajima, Y. Yatabe, K. Takeuchi, T. Hamada, H. Haruta, Y. Ishikawa, H. Kimura, T. Mitsudomi, Y. Tanio, H. Mano; ALK Lung Cancer Study Group, EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N. Engl. J. Med 363, 1734-1739 (2010).
30. W. Pao, J. Chmielecki, Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat. Rev. Cancer 10, 760-774 (2010).
31. G. R. Oxnard, P. C. Lo, M. Nishino, S. E. Dahlberg, N. I. Lindeman, M. Butaney, D. M. Jackman, B. E. Johnson, P. A. Jänne, Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions. J. Thorac. Oncol. 8, 179-184 (2013).
32. M. E. Arcila, K. Nafa, J. E. Chaft, N. Rekhtman, C. Lau, B. A. Reva, M. F. Zakowski, M. G. Kris, M. Ladanyi, EGFR exon 20 insertion mutations in lung adenocarcinomas: Prevalence, molecular heterogeneity, and clinicopathologic characteristics. Mol. Cancer Ther. 12, 220-229 (2013).
33. S. Murray, I. J. Dahabreh, H. Linardou, M. Manoloukos, D. Bafaloukos, P. Kosmidis, Somatic mutations of the tyrosine kinase domain of epidermal growth factor receptor and tyrosine kinase inhibitor response to TKIs in non-small cell lung cancer: An analytical database. J. Thorac. Oncol. 3, 832-839 (2008).
34. H. Linardou, I. J. Dahabreh, D. Bafaloukos, P. Kosmidis, S. Murray, Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC. Nat. Rev. Clin. Oncol. 6, 352-366 (2009).
35. H. Yasuda, S. Kobayashi, D. B. Costa, EGFR exon 20 insertion mutations in non-small-cell lung cancer: Preclinical data and clinical implications. Lancet Oncol. 13, e23-e31 (2012).
36. S. Kobayashi, T. J. Boggon, T. Dayaram, P. A. Jänne, O. Kocher, M. Meyerson, B. E. Johnson, M. J. Eck, D. G. Tenen, B. Halmos, EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 352, 786-792 (2005).
37. S. Kobayashi, H. Ji, Y. Yuza, M. Meyerson, K. K. Wong, D. G. Tenen, B. Halmos, An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor. Cancer Res. 65, 7096-7101 (2005).
38. C. H. Yun, T. J. Boggon, Y. Li, M. S. Woo, H. Greulich, M. Meyerson, M. J. Eck, Structures of lung cancer-derived EGFR mutants and inhibitor complexes: Mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell 11, 217-227 (2007).
39. K. D. Carey, A. J. Garton, M. S. Romero, J. Kahler, S. Thomson, S. Ross, F. Park, J. D. Haley, N. Gibson, M. X. Sliwkowski, Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib. Cancer Res. 66, 8163-8171 (2006).
40. L. V. Sequist, B. Besse, T. J. Lynch, V. A. Miller, K. K. Wong, B. Gitlitz, K. Eaton, C. Zacharchuk, A. Freyman, C. Powell, R. Ananthakrishnan, S. Quinn, J. C. Soria, Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: Results of a phase II trial in patients with advanced non-small-cell lung cancer. J. Clin. Oncol. 28, 3076-3083 (2010).
41. D. A. Eberhard, B. E. Johnson, L. C. Amler, A. D. Goddard, S. L. Heldens, R. S. Herbst, W. L. Ince, P. A. Jänne, T. Januario, D. H. Johnson, P. Klein, V. A. Miller, M. A. Ostland, D. A. Ramies, D. Sebisanovic, J. A. Stinson, Y. R. Zhang, S. Seshagiri, K. J. Hillan, Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J. Clin. Oncol. 23, 5900-5909 (2005).
42. J. Y. Wu, S. G. Wu, C. H. Yang, C. H. Gow, Y. L. Chang, C. J. Yu, J. Y. Shih, P. C. Yang, Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response. Clin. Cancer Res. 14, 4877-4882 (2008).
43. T. Harada, A. Lopez-Chavez, L. Xi, M. Raffeld, Y. Wang, G. Giaccone, Characterization of epidermal growth factor receptor mutations in non-small-cell lung cancer patients of African-American ancestry. Oncogene 30, 1744-1752 (2011).
44. H. Sasaki, K. Endo, M. Takada, M. Kawahara, N. Kitahara, H. Tanaka, M. Okumura, A. Matsumura, K. Iuchi, T. Kawaguchi, O. Kawano, H. Yukiue, T. Yokoyama, M. Yano, Y. Fujii, EGFR exon 20 insertion mutation in Japanese lung cancer. Lung Cancer 58, 324-328 (2007).
45. B. A. Weir, M. S. Woo, G. Getz, S. Perner, L. Ding, R. Beroukhim, W. M. Lin, M. A. Province, A. Kraja, L. A. Johnson, K. Shah, M. Sato, R. K. Thomas, J. A. Barletta, I. B. Borecki, S. Broderick, A. C. Chang, D. Y. Chiang, L. R. Chirieac, J. Cho, Y. Fujii, A. F. Gazdar, T. Giordano, H. Greulich, M. Hanna, B. E. Johnson, M. G. Kris, A. Lash, L. Lin, N. Lindeman, E. R. Mardis, J. D. McPherson, J. D. Minna, M. B. Morgan, M. Nadel, M. B. Orringer, J. R. Osborne, B. Ozenberger, A. H. Ramos, J. Robinson, J. A. Roth, V. Rusch, H. Sasaki, F. Shepherd, C. Sougnez, M. R. Spitz, M. S. Tsao, D. Twomey, R. G. Verhaak, G. M. Weinstock, D. A. Wheeler, W. Winckler, A. Yoshizawa, S. Yu, M. F. Zakowski, Q. Zhang, D. G. Beer, I. I. Wistuba, M. A. Watson, L. A. Garraway, M. Ladanyi, W. D. Travis, W. Pao, M. A. Rubin, S. B. Gabriel, R. A. Gibbs, H. E. Varmus, R. K. Wilson, E. S. Lander, M. Meyerson, Characterizing the cancer genome in lung adenocarcinoma. Nature 450, 893-898 (2007).
46. J. A. Engelman, K. Zejnullahu, C. M. Gale, E. Lifshits, A. J. Gonzales, T. Shimamura, F. Zhao, P. W. Vincent, G. N. Naumov, J. E. Bradner, I. W. Althaus, L. Gandhi, G. I. Shapiro, J. M. Nelson, J. V. Heymach, M. Meyerson, K. K. Wong, P. A. Jänne, PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res. 67, 11924-11932 (2007).
47. D. Li, L. Ambrogio, T. Shimamura, S. Kubo, M. Takahashi, L. R. Chirieac, R. F. Padera, G. I. Shapiro, A. Baum, F. Himmelsbach, W. J. Rettig, M. Meyerson, F. Solca, H. Greulich, K. K. Wong, BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 27, 4702-4711 (2008).
48. X. Zhang, J. Gureasko, K. Shen, P. A. Cole, J. Kuriyan, An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 125, 1137-1149 (2006).
49. N. Jura, Y. Shan, X. Cao, D. E. Shaw, J. Kuriyan, Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3. Proc. Natl. Acad. Sci. U.S.A. 106, 21608-21613 (2009).
50. M. J. Eck, C. H. Yun, Structural and mechanistic underpinnings of the differential drug sensitivity of EGFR mutations in non-small cell lung cancer. Biochim. Biophys. Acta 1804, 559-566 (2010).
51. J. Y. Wu, C. J. Yu, Y. C. Chang, C. H. Yang, J. Y. Shih, P. C. Yang, Effectiveness of tyrosine kinase inhibitors on "uncommon" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer. Clin. Cancer Res. 17, 3812-3821 (2011).
52. D. B. Costa, K. S. Nguyen, B. C. Cho, L. V. Sequist, D. M. Jackman, G. J. Riely, B. Y. Yeap, B. Halmos, J. H. Kim, P. A. Jänne, M. S. Huberman, W. Pao, D. G. Tenen, S. Kobayashi, Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib. Clin. Cancer Res. 14, 7060-7067 (2008).
53. J. Baselga, D. Rischin, M. Ranson, H. Calvert, E. Raymond, D. G. Kieback, S. B. Kaye, L. Gianni, A. Harris, T. Bjork, S. D. Averbuch, A. Feyereislova, H. Swaisland, F. Rojo, J. Albanell, Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J. Clin. Oncol. 20, 4292-4302 (2002).
54. M. Hidalgo, L. L. Siu, J. Nemunaitis, J. Rizzo, L. A. Hammond, C. Takimoto, S. G. Eckhardt, A. Tolcher, C. D. Britten, L. Denis, K. Ferrante, D. D. Von Hoff, S. Silberman, E. K. Rowinsky, Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J. Clin. Oncol. 19, 3267-3279 (2001).
55. T. A. Yap, L. Vidal, J. Adam, P. Stephens, J. Spicer, H. Shaw, J. Ang, G. Temple, S. Bell, M. Shahidi, M. Uttenreuther-Fischer, P. Stopfer, A. Futreal, H. Calvert, J. S. de Bono, R. Plummer, Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. J. Clin. Oncol. 28, 3965-3972 (2010).
56. R. Mulloy, A. Ferrand, Y. Kim, R. Sordella, D. W. Bell, D. A. Haber, K. S. Anderson, J. Settleman, Epidermal growth factor receptor mutants from human lung cancers exhibit enhanced catalytic activity and increased sensitivity to gefitinib. Cancer Res. 67, 2325-2330 (2007).
57. C. H. Yun, K. E. Mengwasser, A. V. Toms, M. S. Woo, H. Greulich, K. K. Wong, M. Meyerson, M. J. Eck, The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc. Natl. Acad. Sci. U.S.A. 105, 2070-2075 (2008).
58. W. Zhou, D. Ercan, L. Chen, C. H. Yun, D. Li, M. Capelletti, A. B. Cortot, L. Chirieac, R. E. Iacob, R. Padera, J. R. Engen, K. K. Wong, M. J. Eck, N. S. Gray, P. A. Jänne, Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature 462, 1070-1074 (2009).
59. H. J. Lee, G. Schaefer, T. P. Heffron, L. Shao, X. Ye, S. Sideris, S. Malek, E. Chan, M. Merchant, H. La, S. Ubhayakar, R. L. Yauch, V. Pirazzoli, K. Politi, J. Settleman, Noncovalent wild-type-sparing inhibitors of EGFR T790M. Cancer Discov. 3, 168-181 (2013).
60. J. Cho, L. Chen, N. Sangji, T. Okabe, K. Yonesaka, J. M. Francis, R. J. Flavin, W. Johnson, J. Kwon, S. Yu, H. E. Greulich, B. E. Johnson, M. J. Eck, P. A. Janne, K. K. Wong, M. Meyerson, Cetuximab response of lung cancer-derived EGF receptor mutants is associated with asymmetric dimerization. Cancer Res. 73, 6770-6779 (2013).
61. A. O. Walter, S. R. Tjin Tham, H. J. Haringsma, K. Ohashi, J. Sun, K. Lee, A. Dubrovskiy, M. Labenski, Z. Zhu, Z. Wang, M. Sheets, T. St Martin, R. Karp, D. van Kalken, P. Chaturvedi, D. Niu, M. Nacht, R. C. Petter, W. Westlin, K. Lin, S. Jaw-Tsai, M. Raponi, T. Van Dyke, J. Etter, Z. Weaver, W. Pao, J. Singh, A. D. Simmons, T. C. Harding, A. Allen, Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC. Cancer Discov. 10.1158/2159-8290.CD-13-0314 (2013).
62. Y. Minami, T. Shimamura, K. Shah, T. LaFramboise, K. A. Glatt, E. Liniker, C. L. Borgman, H. J. Haringsma, W. Feng, B. A. Weir, A. M. Lowell, J. C. Lee, J. Wolf, G. I. Shapiro, K. K. Wong, M. Meyerson, R. K. Thomas, The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272. Oncogene 26, 5023-5027 (2007).
63. L. V. Sequist, J. von Pawel, E. G. Garmey, W. L. Akerley, W. Brugger, D. Ferrari, Y. Chen, D. B. Costa, D. E. Gerber, S. Orlov, R. Ramlau, S. Arthur, I. Gorbachevsky, B. Schwartz, J. H. Schiller, Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. J. Clin. Oncol. 29, 3307-3315 (2011).
64. W. L. Yeo, G. J. Riely, B. Y. Yeap, M. W. Lau, J. L. Warner, K. Bodio, M. S. Huberman, M. G. Kris, D. G. Tenen, W. Pao, S. Kobayashi, D. B. Costa, Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations. J. Thorac. Oncol. 5, 1048-1053 (2010).
65. R. K. Thomas, A. C. Baker, R. M. Debiasi, W. Winckler, T. LaFramboise, W. M. Lin, M. Wang, W. Feng, T. Zander, L. MacConaill, J. C. Lee, R. Nicoletti, C. Hatton, M. Goyette, L. Girard, K. Majmudar, L. Ziaugra, K. K. Wong, S. Gabriel, R. Beroukhim, M. Peyton, J. Barretina, A. Dutt, C. Emery, H. Greulich, K. Shah, H. Sasaki, A. Gazdar, J. Minna, S. A. Armstrong, I. K. Mellinghoff, F. S. Hodi, G. Dranoff, P. S. Mischel, T. F. Cloughesy, S. F. Nelson, L. M. Liau, K. Mertz, M. A. Rubin, H. Moch, M. Loda, W. Catalona, J. Fletcher, S. Signoretti, F. Kaye, K. C. Anderson, G. D. Demetri, R. Dummer, S. Wagner, M. Herlyn, W. R. Sellers, M. Meyerson, L. A. Garraway, High-throughput oncogene mutation profiling in human cancer. Nat. Genet. 39, 347-351 (2007).
66. A. J. McCoy, R. W. Grosse-Kunstleve, P. D. Adams, M. D. Winn, L. C. Storoni, R. J. Read, Phaser crystallographic software. J. Appl. Crystallogr. 40, 658-674 (2007).
67. A. T. Brünger, P. D. Adams, G. M. Clore, W. L. DeLano, P. Gros, R. W. Grosse-Kunstleve, J. S. Jiang, J. Kuszewski, M. Nilges, N. S. Pannu, R. J. Read, L. M. Rice, T. Simonson, G. L. Warren, Crystallography & NMR system: A new software suite for macromolecular structure determination. Acta Crystallogr. D Biol. Crystallogr. 54, 905-921 (1998).
68. P. Emsley, K. Cowtan, Coot: Model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60, 2126-2132 (2004).
69. G. N. Murshudov, A. A. Vagin, E. J. Dodson, Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr. D Biol. Crystallogr. 53, 240-255 (1997).
70. A. W. Schüttelkopf, D. M. van Aalten, PRODRG: A tool for high-throughput crystallography of protein-ligand complexes. Acta Crystallogr. D Biol. Crystallogr. 60, 1355-1363 (2004).